XORTX plans FDA IND filing for gout drug in Q4 2026 Sep 18, 2026 08:05AM
XORTX begins manufacturing of gout drug candidate XORLO Sep 10, 2026 04:07PM
XORTX cancels $2.5M investor relations deal, delays TSXV delisting Aug 28, 2026 07:01AM
XORTX board chairman Anthony Giovinazzo resigns Jul 31, 2026 05:00PM
XORTX appoints Mika Grasso as co-CEO, advances gout drug program Jun 15, 2026 07:03AM


Jun 12, 2026 05:01PM XORTX to voluntarily delist from TSX Venture Exchange
Apr 21, 2026 07:02AM XORTX regains Nasdaq compliance after reverse stock split
Feb 4, 2026 06:01PM XORTX extends deadline to complete Vectus acquisition to March
Dec 31, 2025 08:52PM XORTX adds board member, corrects financing details
Sep 3, 2025 07:02AM XORTX begins IND preparation for gout treatment XORLO
Aug 7, 2025 07:02AM XORTX targets 2026 FDA filing for gout treatment XORLO
May 19, 2025 07:02AM XORTX Therapeutics Inc (XRTX) Announces USD $3 Million Offering Up to 3.4 Million Shares at $0.88 Each
Apr 30, 2025 07:02AM XORTX Therapeutics Inc (XRTX) Provides Update on FDA Type B Meeting Request
Apr 28, 2025 07:00AM XORTX Therapeutics Inc (XRTX) Announces Grant of European Patent
Mar 19, 2025 07:02AM XORTX Therapeutics Inc (XRTX) Announces Update for Discussion with the FDA
Feb 24, 2025 07:03AM XORTX Therapeutics Inc (XRTX) Commences Gout Program NDA Discussions with the FDA
Jan 6, 2025 07:03AM XORTX Therapeutics Inc (XRTX) Adds Late Stage Gout Program to Pipeline
Dec 19, 2024 07:01AM XORTX Therapeutics Inc (XRTX) Announces Management Changes
Oct 17, 2024 08:01AM XORTX Therapeutics Inc (XRTX) Announces 810.81K Share Offering at $2.18/sh
Oct 9, 2024 05:59AM XORTX Therapeutics (XRTX) Initiates Precision Medicine Program